FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/− Mice

• Published in: Neuroscience Vol. 411; pp. 1 - 10
• Main Authors: Vidal-Martinez, Guadalupe, Najera, Katherine, Miranda, Julie D., Gil-Tommee, Carolina, Yang, Barbara, Vargas-Medrano, Javier, Diaz-Pacheco, Valeria, Perez, Ruth G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 15.07.2019
• Subjects: alpha-Synuclein - metabolism; Animals; Behavior, Animal - drug effects; brachial plexus synucleinopathy; Brain - drug effects; Brain - metabolism; Brain-Derived Neurotrophic Factor - metabolism; Fingolimod Hydrochloride - pharmacology; Fingolimod Hydrochloride - therapeutic use; improved bladder function; low dose drug; Mice; Mice, Transgenic; motor improvement; Motor Skills - drug effects; myelination biomarker increases; N-Acetylgalactosaminyltransferases - genetics; N-Acetylgalactosaminyltransferases - metabolism; neuroprotection; Parkinson Disease, Secondary - drug therapy; Parkinson Disease, Secondary - metabolism; Rotarod Performance Test; Sphingosine 1 Phosphate Receptor Modulators - pharmacology; Sphingosine 1 Phosphate Receptor Modulators - therapeutic use; brachial plexus synucleinopathy; motor improvement; myelination biomarker increases; improved bladder function; neuroprotection; low dose drug

Parkinson's disease (PD) is a progressive aging disorder that affects millions worldwide, thus, disease-modifying-therapies are urgently needed. PD pathology includes α-synuclein (aSyn) accumulation as synucleinopathy. Loss of GM1 gangliosides occurs in PD brain, which is modeled in GM2 synthas...